跳至主要内容
临床试验/JPRN-jRCTs041210108
JPRN-jRCTs041210108招募中未知

A multicenter randomized clinical trial of ipilimumab plus nivolumab with prophlactic dexamethasone therapy in patients with advanced renal cell carcinoma comparing with a historical control trearted with traditional ipilimumab plus nivolumab therapy.

Hamamoto Shuzo0 个研究点目标入组 90 人开始时间: 2021年11月24日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 90age old(—)
性别
All

入选标准

  • (1) 20-90 years old patients who were diagnosed as advanced renal cell carcinoma and had an indication for Ipilimumab plus nivolumab therapy
  • (2) Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1, 2, or 3
  • (3) labolatory data includes the following criteria
  • a) WBC: more than 3,000 /mm3
  • b) Hb: more than 8.0g/dL
  • c) PLT: more than 100000/mm3
  • d) AST(GOT), ALT(GPT): AST Less than 66 mg/dL, ALT Less than 54 mg/dL
  • e) Total Bil: Less than 1.5mg/dL
  • (4) Patients who can get hospitalized for this study
  • (5) Patients who were obtained written informed consent

排除标准

  • (1) women with pregnant or its possibily
  • (2) Hisory of Having allegies to ipilimumab or nivolumab therapy
  • (3) active multiple cancer
  • (4) Taking a steroid or immunosuppressive drug
  • (5) uncontoralble diabetes
  • (6) Judged as an inappropriate patient by the investigator or sub-investigator

研究者

发起方
Hamamoto Shuzo

相似试验

Ipilimumab plus nivolumab with prophlactic... | 临床试验